X4 Pharmaceuticals (XFOR) Q1 2026 earnings summary

Executive summary

• Net loss of $20.2 million for Q1 2026, compared to net income of $0.3 million in Q1 2025, driven by lower license revenue and reduced operating expenses.

• Product revenue increased to $2.5 million from $0.9 million year-over-year, reflecting higher patient uptake for the approved drug.

• License and other revenue dropped sharply to $0.2 million from $27.9 million due to non-recurring prior-year license payments.

• Strategic focus remains on commercialization of XOLREMDI and advancing the pivotal Phase 3 4WARD trial for chronic neutropenia, with enrollment on track to complete by end of Q3 2026 and over 110 active sites globally.

• European Commission approved XOLREMDI for WHIM syndrome, marking the first authorized treatment for this condition in the EU; commercialization will be led by partner Norgine.

Financial highlights

• Total revenue for Q1 2026 was $2.7 million, down from $28.8 million in Q1 2025, mainly due to the absence of large license revenue.

• Operating expenses decreased to $23.0 million from $38.2 million year-over-year, reflecting restructuring and lower G&A costs.

• Net cash used in operating activities was $19.6 million for Q1 2026, compared to $12.4 million in Q1 2025.

• Cash, cash equivalents, and marketable securities totaled $233.7 million as of March 31, 2026.

• Net loss for Q1 2026 was $(20.2) million, or $(0.16) per share, compared to net income of $0.3 million, or $0.04 per share, in Q1 2025.

Outlook and guidance

• Current cash and marketable securities expected to fund operations for at least the next 12 months.

• Full enrollment for the 4WARD Phase 3 trial anticipated by end of Q3 2026.

• Expects to receive up to €226 million in milestone payments and escalating royalties from Norgine based on regulatory and commercial achievements.

• Continued operating losses expected as clinical development progresses; additional capital may be needed beyond the next year.

• Anticipates smooth transfer of EU marketing authorization to Norgine and subsequent commercialization.